What's New
News
Open Hand Foundation Provides AFTD $600K for FTD Research
AFTD is pleased to announce that we have received a gift of $600,000 from the Open Hand…
Provide Help and Bring Hope with a Year-End Gift
AFTD was founded more than 20 years ago with a single donation. Since then, the dedication and…
U.S. Rep. Jennifer Wexton Announces Progressive Supranuclear Palsy Diagnosis
Representative Jennifer Wexton of Virginia announced last week that she would not be seeking re-election after receiving…
AFTD and Passage Bio Discuss Therapeutics Designed for FTD-GRN
AFTD recently spoke with Passage Bio Chief Executive Officer William Chou, M.D., about his colleagues’ work to…
AFTD and Denali Therapeutics Discuss Takeda Pharmaceuticals Partnership to Develop FTD-Focused Therapeutic
Recently, members of the Denali Therapeutics team provided insights into their work and partnership with Takeda to…
One-Night Performance of Acclaimed Play UnRavelled Examines Art, Science, and Dementia
AFTD staff and Board members attended a performance of the play UnRavelled at the San Francisco Conservatory…
AFTD and AviadoBio Discuss Therapeutic Treatment Protocols for FTD
AFTD recently spoke with AviadoBio Chief Executive Officer Lisa Deschamps about her colleagues’ work to develop a…
Groundbreaking Drug That Slows Progression of Alzheimer’s Receives Full FDA Approval
The U.S. Food and Drug Administration (FDA) has, for the first time, fully approved a drug that…
Dr. Chiadi Onyike Named AFTD Medical Advisory Council Chair-Elect
During their annual meeting at the 2023 Education Conference, AFTD’s Board of Directors named Chiadi Onyike, MD,…
Wave Life Sciences Ends FTD/ALS Trial of WVE-004
Yesterday, Wave Life Sciences announced that it ended its FOCUS-C9 clinical trial for the drug WVE-004, which…
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)